Triglyceride-glucose index variability and incident cardiovascular disease: a prospective cohort study. 2022

Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
Department of Cardiac Surgery, Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Recent studies have suggested that triglyceride-glucose (TyG) index is an independent predictor of cardiovascular disease (CVD). However, the impact of long-term visit-to-visit variability in TyG index on the risk of CVD is not known. We aimed to investigate the longitudinal association between baseline and mean TyG index as well as TyG index variability and incident CVD in a Chinese population. We included 49,579 participants without previous history of CVD in the Kailuan study who underwent three health examinations (2006, 2008, and 2010) and were followed up for clinical events until 2019. TyG index was calculated as Ln [fasting triglyceride (mg/dL) × fasting glucose (mg/dL)/2]. We measured TyG index variability as the SD of the residuals obtained from a linear regression on the three TyG index measurements for each individual. Multivariate-adjusted Cox models were used to estimate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) with incident CVD. During a median follow-up time of 9.0 years, 2404 developed CVD. The highest tertile (T3) of baseline and mean TyG index were each associated with higher CVD incidence as compared with the lowest tertile (T1): aHR, 1.25; 95% CI 1.11-1.42; and aHR 1.40; 95% CI 1.24-1.58, respectively. Tertile 3 of TyG index variability was associated with increased CVD incidence compared to T1 group (aHR, 1.12; 95% CI 1.01-1.24). Similar findings were observed in a series of sensitivity analyses. Higher TyG index level and greater TyGindex variability were each independently associated with a higher incidence of CVD.

UI MeSH Term Description Entries
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D014280 Triglycerides An ester formed from GLYCEROL and three fatty acid groups. Triacylglycerol,Triacylglycerols,Triglyceride
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
December 2023, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
April 2024, Zhonghua xin xue guan bing za zhi,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
December 2025, Cardiovascular diabetology,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
January 2025, Frontiers in cardiovascular medicine,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
November 2023, Cardiovascular diabetology,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
October 2023, Diabetology & metabolic syndrome,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
November 2025, Cardiovascular diabetology,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
November 2022, Diabetes & metabolism,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
October 2025, The journals of gerontology. Series A, Biological sciences and medical sciences,
Haibin Li, and Yingting Zuo, and Frank Qian, and Shuohua Chen, and Xue Tian, and Penglian Wang, and Xia Li, and Xiuhua Guo, and Shouling Wu, and Anxin Wang
December 2023, Cardiovascular diabetology,
Copied contents to your clipboard!